GENFARMA OFFICIALLY RECEIVES GMP CERTIFICATION
A Milestone Affirming Manufacturing Excellence - The Beginning of Genfarma's Journey to Master Biotechnology in Vietnam
"Every milestone we achieve today is not only a reflection of our accomplishments, but also a commitment to the future."
On 28 July 2026, Genfarma Joint Stock Company officially held the GMP Certificate Awarding Ceremony, celebrating the receipt of the Good Manufacturing Practice (GMP) certificate granted by the Drug Administration of Vietnam (DAV), Ministry of Health. The event also marked another strategic milestone in the Company's long-term development journey under the theme:
LÀM CHỦ CÔNG NGHỆ – KIẾN TẠO TƯƠNG LAI
Mastering Technology. Shaping The Future.
The event not only signifies that Genfarma's manufacturing facility has officially met the stringent requirements of Good Manufacturing Practice (GMP), but also heralds a new chapter in the Company's commitment to investing in, mastering, and advancing biotechnology to deliver innovative therapeutic solutions for Vietnam.
The ceremony was honored by the presence of distinguished guests, including representatives of the Drug Administration of Vietnam (Ministry of Health), the Ambassador Extraordinary and Plenipotentiary of the Republic of Cuba to Vietnam, representatives from the Ministry of Foreign Affairs, government authorities, research institutes, universities, hospitals, as well as domestic and international partners who joined Genfarma in celebrating this significant milestone.
.jpg)
More Than a Certification - The Beginning of a New Journey
In the pharmaceutical industry, Good Manufacturing Practice (GMP) is internationally recognized as the benchmark ensuring that pharmaceutical manufacturing systems consistently meet stringent requirements for quality, safety, and product consistency.
For Genfarma, however, GMP represents much more than a manufacturing standard.
It is a milestone that reflects the Company's systematic investment in manufacturing infrastructure, quality management systems, and highly qualified professionals. More importantly, it establishes a solid foundation for Genfarma to continue researching, acquiring, and mastering advanced biotechnology, thereby contributing to the long-term self-reliance and sustainable development of Vietnam's pharmaceutical industry.
The Capability That Makes Genfarma Different
Genfarma adopts an integrated development model encompassing research and development (R&D), technology transfer, GMP-compliant manufacturing, and the development of highly qualified talent. With this strong foundation, the Company is steadily building its capability to master advanced biotechnology, creating sustainable competitive advantages while contributing to the enhanced self-reliance of Vietnam's pharmaceutical industry.
.jpg)
Genfarma Officially Receives the Good Manufacturing Practice (GMP) Certificate
The Aspiration to Master Advanced Biotechnology
A key highlight of the event was Genfarma's official announcement of its long-term development strategy, reaffirming the Company's commitment to progressively mastering advanced biotechnologies, particularly monoclonal antibody technology.
Today, monoclonal antibody technology serves as the foundation for numerous innovative therapies in the treatment of cancer, autoimmune diseases, and rare diseases worldwide. By acquiring and progressively mastering this technology, Genfarma is laying a solid foundation for the future development and domestic manufacturing of high-value biopharmaceuticals in Vietnam.
For many years, biological therapies for cancer and other complex diseases have largely relied on imported products, often associated with high treatment costs. Strengthening domestic capabilities in research, technology transfer, and pharmaceutical manufacturing will not only expand patients' access to advanced therapies but also enhance the self-reliance of Vietnam's pharmaceutical industry.
This is the long-term vision that Genfarma remains firmly committed to pursuing.
.jpg)
Genfarma CEO Mr. Bùi Lê Khoa shares the Company's vision for development and its strategic commitment to mastering biotechnology.
"GMP is not the destination, but the foundation upon which Genfarma will progressively master biotechnology, contributing to the self-reliance of Vietnam's pharmaceutical industry."
Investing Today, Building Tomorrow's Capabilities
Alongside the development of its GMP-certified manufacturing facility, Genfarma continues to make significant investments in:
* State-of-the-art automated manufacturing systems
* Research and Development (R&D)
* Quality control laboratories that meet international standards
* The development of highly qualified scientific and technical experts
* Expanding technology transfer partnerships with international collaborators
In particular, the successful acquisition of monoclonal antibody technology has established a critical foundation for Genfarma to progressively access, master, and advance cutting-edge biotechnologies for the treatment of cancer and other complex diseases.
.jpg)
Genfarma embarks on a strategic investment phase to strengthen manufacturing capabilities and drive innovation
From Manufacturing Infrastructure to Innovation Capability
During the ceremony, representatives of the Drug Administration of Vietnam (DAV) highly commended Genfarma's investment efforts in building an internationally compliant manufacturing system and advancing cutting-edge biotechnologies.
This recognition extends beyond the achievements of a single enterprise. It also reaffirms the strategic direction of Vietnam's pharmaceutical industry toward modernization, innovation, and the progressive mastery of advanced technologies.
.jpg)
A representative of the Drug Administration of Vietnam delivers remarks at the event
Shaping the Future Through Science and Responsibility
Looking ahead, Genfarma will continue to expand its investments in research, talent development, and international collaboration to strengthen Vietnam's biopharmaceutical value chain.
Every production line expanded.
Every technology acquired.
Every product researched.
All are driven by one shared purpose:
To deliver safer, more effective, and high-quality treatment solutions for Vietnamese patients.
This is also the spirit embodied in our message:
Mastering Technology. Shaping the Future.
Genfarma believes that when science is guided by responsibility, innovation is fueled by aspiration, and advanced technologies are mastered by Vietnamese expertise, the future of Vietnam's biopharmaceutical industry begins to take shape today.
.jpg)
Genfarma is committed to mastering technology and shaping the future
Partnering to Shape the Future of Vietnam's Biopharmaceutical Industry
The journey toward mastering biotechnology is a long-term commitment that requires sustained investment, a spirit of continuous innovation, and close collaboration among all stakeholders. Genfarma believes that only through strong partnerships with regulatory authorities, research institutes, universities, hospitals, domestic and international partners, and the scientific community can we build a robust biopharmaceutical ecosystem that strengthens the self-reliance of Vietnam's pharmaceutical industry.
Looking ahead, Genfarma will continue to invest in research and development (R&D), expand technology transfer partnerships, cultivate highly qualified talent, and enhance its manufacturing capabilities in accordance with international standards. Every step forward is driven not only by the ambition to master advanced biotechnologies, but also by the commitment to delivering safer, more effective, and high-quality treatment solutions for Vietnamese patients.
Mastering Technology. Shaping The Future.
Driven by the aspiration to master technology, a spirit of continuous innovation, and a strong sense of responsibility toward the community, Genfarma remains committed to working alongside its partners, scientists, healthcare professionals, and the broader pharmaceutical community to build a sustainable future for Vietnam's biopharmaceutical industry—where scientific achievements are transformed into meaningful value for people's health.